2022
Predictors of abstinence, no heavy drinking days, and a 2‐level reduction in World Health Organization drinking levels during treatment for alcohol use disorder in the COMBINE study
Wallach JD, Gueorguieva R, Phan H, Witkiewitz K, Wu R, O'Malley SS. Predictors of abstinence, no heavy drinking days, and a 2‐level reduction in World Health Organization drinking levels during treatment for alcohol use disorder in the COMBINE study. Alcohol Clinical And Experimental Research 2022, 46: 1331-1339. PMID: 35616436, PMCID: PMC9887652, DOI: 10.1111/acer.14877.Peer-Reviewed Original ResearchConceptsHeavy drinking daysWeeks of treatmentAlcohol use disorderDependence Scale scoresDrinking daysScale scoreDays abstinentPredictors of abstinenceConsecutive weeksUse disordersDrinking levelsCOMBINE StudyOlder subjectsRandomized placebo-controlled trialPlacebo-controlled trialEfficacy of naltrexoneMultiple patient characteristicsTrials of medicationsBehavioral intervention studyPatient characteristicsFuture trialsBaseline variablesCombined PharmacotherapiesYoung subjectsComplete abstinence
2017
Mecamylamine treatment for alcohol dependence: a randomized controlled trial
Petrakis IL, Ralevski E, Gueorguieva R, O'Malley SS, Arias A, Sevarino KA, Jane JS, O'Brien E, Krystal JH. Mecamylamine treatment for alcohol dependence: a randomized controlled trial. Addiction 2017, 113: 6-14. PMID: 28710873, PMCID: PMC5725262, DOI: 10.1111/add.13943.Peer-Reviewed Original ResearchConceptsHeavy drinking daysDrinking daysAlcohol use disorderUse disordersAlcohol consumptionAlcohol dependenceDouble-blind clinical trialNicotinic acetylcholine receptor antagonistWeeks of treatmentAcetylcholine receptor antagonistCurrent alcohol dependenceSignificant differencesTreatment-seeking smokersMecamylamine treatmentPlacebo groupMonth 3Primary outcomeSmoking statusNicotine withdrawalReceptor antagonistNovel pharmacotherapiesClinical trialsManagement therapyMecamylamineTreatment groups
2006
Effects of Naltrexone on Cognition in a Treatment Study of Patients with Schizophrenia and Comorbid Alcohol Dependence
Ralevski E, Balachandra K, Gueorguieva R, Limoncelli D, Petrakis I. Effects of Naltrexone on Cognition in a Treatment Study of Patients with Schizophrenia and Comorbid Alcohol Dependence. Journal Of Dual Diagnosis 2006, 2: 53-69. DOI: 10.1300/j374v02n04_05.Peer-Reviewed Original ResearchCognitive functioningAlcohol dependenceFrontal lobe functioningComorbid alcohol dependenceSymptoms of schizophreniaAlcohol useFunctioningCognitionTreatment studiesSchizophreniaEffects of naltrexoneAlcohol reductionMemoryDrinking patternsAlcohol consumptionAttentionSecond objectiveWeeks of treatmentDeficitsFirst objectiveWeek 24Naltrexone treatmentWeek 12NaltrexonePatients